Acutaas Chemicals Limited – Investor Presentation Summary

Key Operational Highlights

  • Revenue from operations reached ₹4,369 million in Q2 FY27, representing 42.7% year-on-year growth
  • Pharmaceutical Intermediates business delivered robust growth through both CDMO and Core Advanced intermediate segments
  • Specialty Chemicals segment declined due to strategic phasing out of commodity chemicals and impact from ownership change of US customer in BFC business
  • South Korea manufacturing facility inaugurated ahead of schedule, equipped to produce high-purity chemicals for photoresists, semiconductor packaging materials, etching materials and other semiconductor applications

Segment-wise Performance

  • Pharmaceutical Intermediates: Strong performance with robust growth in both CDMO and Core Advanced intermediate business
  • Specialty Chemicals: Decline due to strategic reduction in commodity chemicals and BFC business impact from US customer ownership change

Financial Highlights

Revenue: ₹4,369 million (Q2 FY27)

EBITDA: ₹1,760 million (Q2 FY27)

PAT: ₹1,231 million (Q2 FY27)

EPS: Not specified

Margins: Gross Margin 62.1%, EBITDA Margin 40.3%, PAT Margin 28.2% (Q2 FY27)

YoY comparison: Revenue ▲42.7%, EBITDA ▲84.6%, PAT ▲71.4% (Q2 FY27 vs Q2 FY26)

QoQ comparison: Revenue ▲32.5%, EBITDA ▲55.6%, PAT ▲64.2% (Q2 FY27 vs Q1 FY27)

H1 FY27 performance: Revenue ₹7,666 million (▲49.3% YoY), EBITDA ₹2,890 million (▲97.7% YoY), PAT ₹1,981 million (▲71.0% YoY)

Drivers of financial performance: Higher gross margins, operating leverage, strong Pharmaceutical Intermediates growth

Comparison to market estimates: Not specified

Key Risks: Not disclosed

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not specified

Regional Breakdown: Not specified

Balance Sheet Snapshot

Net Debt/Equity: Not specified

Reserves: Not specified

Current Assets/Liabilities: Current Assets ₹10,120 million, Current Liabilities ₹2,534 million (H1 FY27)

Working Capital/Leverage Metrics: Not specified

Financial Health Insights: Strong cash position with Cash and cash equivalents ₹2,888 million, Total assets ₹22,209 million (H1 FY27)

Capex & Cash Flow Health

Capital Expenditure: Not specified for current period

Free Cash Flow: Not specified

Operating Cash Flow: Not specified

Net Debt Movement: Not disclosed

Investment Rationale: South Korea facility positioning for semiconductor ecosystem opportunities

Strategic & R&D Initiatives

Investments in Innovation: South Korea manufacturing facility for high-purity semiconductor chemicals

Expected impact on growth: Positioned to capitalize on fast-growing semiconductor ecosystem

Strategic Rationale: Expansion into high-growth semiconductor materials market

Industry Trends & Business Environment

Macro/Industry Trends: Fast-growing semiconductor ecosystem

Impact on Company: New South Korea facility specifically designed to address semiconductor industry opportunities

Management Commentary & Growth Outlook

Strategic Outlook: "Improved revenue visibility and robust order pipeline gives me confidence to revise our FY27 revenue growth guidance upward" - Mr. Naresh Patel, Executive Chairman and Managing Director

FY Guidance: Revenue growth guidance revised upward from 25% to around 30%; EBITDA margin guidance raised to 38-40% range

Market Share Targets: Not specified

Risks and Opportunities: Not specified beyond general forward-looking statement disclaimer